| Date |
Title |
|
|
|
12/06/19
|
ANN ARBOR, Mich. , Dec. 06, 2019 (GLOBE NEWSWIRE) -- Gemphire Therapeutics Inc. (NASDAQ:GEMP) announced today that, based upon the final vote count certified by the independent inspector of elections for the annual meeting of stockholders held December 6, 2019 , its stockholders approved all of the
|
|
|
|
08/09/19
|
LIVONIA, Mich. , Aug. 09, 2019 (GLOBE NEWSWIRE) -- Gemphire Therapeutics Inc. (NASDAQ:GEMP), a clinical-stage biopharmaceutical company developing and commercializing therapies for the treatment of dyslipidemia, a serious medical condition that increases the risk of life-threatening cardiovascular
|
|
|
|
07/24/19
|
Transaction to Create Nasdaq-listed Biotechnology Company Focused on Advancing NeuroBo’s Clinical-Stage Pipeline NeuroBo Poised to Advance Lead Drug Candidate into Phase 3 Trials for Neuropathic Pain Indications NeuroBo Recently Received Aggregate Gross Proceeds of $24.24 Million in Series B
|
|
|
|
06/26/19
|
Gemcabene safely lowered serum triglycerides (TGs), the primary endpoint, in a subset of FPLD patients LIVONIA, Mich. , June 26, 2019 (GLOBE NEWSWIRE) -- Gemphire Therapeutics Inc. (NASDAQ: GEMP) today announced top-line results based upon the Company’s preliminary review of the limited top-line
|
|
|
|
03/15/19
|
LIVONIA, Mich. , March 15, 2019 (GLOBE NEWSWIRE) -- Gemphire Therapeutics Inc. (NASDAQ:GEMP), a clinical-stage biopharmaceutical company focused on developing and commercializing therapies for the treatment of dyslipidemia, a serious medical condition that increases the risk of life-threatening
|
|
|
